Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate of $(0.93) by 9.68 percent. This is a 10.53 percent increase over losses of $(1.14) per share from the same period last year. The company reported quarterly sales of $17.000 million which missed the analyst consensus estimate of $29.484 million by 42.34 percent. This is a 39.29 percent decrease over sales of $28.000 million the same period last year.